Cory Abate-Shen

About

Cory Abate-Shen, PhD, is a Professor of Molecular Pharmacology and Therapeutics, as well as Urologic Sciences, and holds the Robert Sonneborn Professor of Medicine title at Columbia University Vagelos College of Physicians and Surgeons. Her research focuses on the molecular mechanisms of cancer development, with a longstanding commitment to generating mouse models of cancer for translational research. She has developed novel models of prostate and bladder cancer, which are utilized for investigating the molecular basis of these diseases and for evaluating new therapies. Dr. Abate-Shen is an internationally-recognized leader in genitourinary malignancies, with her studies leading to the discovery of new biomarkers for early detection and advances in cancer prevention and treatment. Her career began at Rutgers Medical School in 1991, where she quickly rose through the ranks to become Professor and Chief of the Division of Research in the Department of Medicine, as well as co-leader of the Prostate Program for The Cancer Institute of New Jersey. In 2007, she joined Columbia University, where she has held multiple leadership roles, including Associate Director and Interim Director of the Herbert Irving Comprehensive Cancer Center, before being appointed Chair of the Department of Pharmacology in 2019. Dr. Abate-Shen has received numerous awards, including a Sinsheimer Scholar Award, an NSF Young Investigator Award, and an American Cancer Society Research Professorship. She has…

Selected publications

• A modular master regulator landscape controls cancer transcriptional identity

  Cell · 2021-01-01 · 144 citations

  articleOpen accessCorresponding
  PublisherOA PDFDOI

• Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression

  Nature Cancer · 2021 · 132 citations

  DOI

• NKX3.1 Localization to Mitochondria Suppresses Prostate Cancer Initiation

  Cancer Discovery · 2021-04-23 · 47 citations

  articleOpen accessSenior author

  Abstract Mitochondria provide the first line of defense against the tumor-promoting effects of oxidative stress. Here we show that the prostate-specific homeoprotein NKX3.1 suppresses prostate cancer initiation by protecting mitochondria from oxidative stress. Integrating analyses of genetically engineered mouse models, human prostate cancer cells, and human prostate cancer organotypic cultures, we find that, in response to oxidative stress, NKX3.1 is imported to mitochondria via the chaperone p…

  PublisherOA PDFDOI

• NSD2 targeting reverses plasticity and drug resistance in prostate cancer

  Nature · 2025-11-26 · 7 citations

  articleOpen access

  Lineage plasticity is a cancer hallmark that drives disease progression and treatment resistance1,2. Plasticity is often mediated by epigenetic mechanisms that may be reversible; however, there are few examples of such reversibility. In castration-resistant prostate cancer (CRPC), plasticity mediates resistance to androgen receptor (AR) inhibitors and progression from adenocarcinoma to aggressive subtypes, including neuroendocrine prostate cancer (CRPC-NE)3–5. Here we show that plasticity-associ…

  PublisherDOI

• ATAD2 Drives Prostate Cancer Progression to Metastasis

  Molecular Cancer Research · 2025-02-05 · 3 citations

  articleOpen access

  Metastasis accounts for the overwhelming majority of cancer deaths. In prostate cancer and many other solid tumors, progression to metastasis is associated with drastically reduced survival outcomes, yet the mechanisms behind this progression remain largely unknown. ATPase family AAA domain containing 2 (ATAD2) is an epigenetic reader of acetylated histones that is overexpressed in multiple cancer types and usually associated with poor patient outcomes. However, the functional role of ATAD2 in c…

  PublisherOA PDFDOI

Awards & honors

• Sinsheimer Scholar Award
• NSF Young Investigator Award
• American Cancer Society Research Professorship
• Fellow of the American Association for the Advancement of Sc…

Similar researchers at Columbia University

• René Henh-177
• Jonathan A. Javitchh-121
• Gary W. Millerh-90